WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 262
GDP / capita (US$): 8'5151 Child (under 5 years) mortality rate: 302

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 38'482  37'763  37'063  36'383  35'725  31'719  26'240  19'475 
Births 946  932  911  881  845  621  846  863 
Surviving infants 921  907  885  856  820  598  803  785 
Pop. less than 5 years 4'468  4'287  3'981  3'767  3'528  3'108  4'081  3'553 
Pop. less than 15 years 10'614  10'343  10'051  9'908  9'794  10'847  11'502  8'991 
Female 15-49 years 10'902  10'784  10'672  10'513  10'342  8'597  5'973  4'241 

Number of reported case

(Click for retrospective incidence data for Algeria)
Diphtheria 30  116 
Japanese encephalitis
Measles 18  112  103  107  217  1'796  15'527 
Mumps
Pertussis 104  28  23  710 
Polio* 116 
Rubella 420  170  212  23  1'339 
Rubella (CRS)
Tetanus (neonatal) 27 
Tetanus (total) 38  86 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Algeria)
Vaccine year result method % card seen                                                
BCG 2005  99  MICS   92.4  100  100  100  100  100  65 
DTP1 2005  98  MICS   92.4  100  100  100  98  97 
DTP3 2005  95  MICS   92.4  95  95  95  95  93  58 
HepB_BD          100  100  100  100  100 
HepB3 2005  80  MICS   92.4  95  95  95  94  91 
Hib3          95  95  95  95  93 
JapEnc         
MCV 2005  91  MICS   92.4  95  95  95  92  88  80  53 
MCV2          95  96 
PCV1         
PCV3         
Pol3 2005  94  MICS   92.4  95  95  95  92  81 
Rota1         
Rota_last         
Rubella1         
TT2plus 1999  45  MICS   92.8  57 
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Algeria)
BCG 99  99  99  99  99  97  99 
DTP1 99  99  99  98  97  95  96 
DTP3 95  95  95  95  93  86  89 
HepB3 95  95  95  94  91 
Hib3 95  95  95  95  93 
MCV 95  95  95  92  88  80  83 
PAB 90  90  90  71  71  64  75 
PCV3
Pol3 95  95  95  94  92  86  89 
Rota_last

Number of districts in the country 271  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 6 years; Yes
DTwPHib 3, 4, 5, 18 months; Yes
HepB birth; 1, 5 months; Yes
Measles 9 months; 6 years; Yes
OPV birth; 3, 4, 5, 18 months; 6 years; Yes
Td 11-13, 16-18 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes    Yes  Yes  Yes  Yes 
What years does the MYP cover? number         2006-2009  2006-2009  2006-2009 
Nº of districts with microplans that include activities to raise immunization coverage number       271  185  185 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 271  271  271  464  276  185  185 
Nº districts with DTP3 coverage >=80% number   44  193         
% of districts with DTP3 coverage >=80% From 0 to 100%   16  71         
Nº districts with measles (MCV1) coverage >=95% number   81         
% of districts with MCV1 coverage >=95% From 0 to 100%   30       

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes    Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes    Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100    100  100  100  100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.